Navigation Links
Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
Date:8/21/2012

BOSTON, Aug. 21, 2012 /PRNewswire/ -- Sequence, Inc. and PCI, LLC, leaders in the fields of regulatory compliance and pharmaceutical calibration respectively, have announced the collaborative opening of a new office in the Innovation District of Boston, Massachusetts.

Establishing a Boston office provides Sequence and PCI an opportunity to extend service offerings to new and existing clients in the New England biotech and pharmaceutical sectors. "The coupling of validation and calibration services presents our clients with a streamlined approach to quality. It will reduce cost and expedite time to market for life-saving drugs benefiting our customers and patients alike.  We are proud to partner with PCI, a firm well known as the distinguished leader in calibration services," said Mike Putnam, President of Sequence, Inc.

"For some time now, a New England presence has been a key part of our expansion plans," said Andy Ferrell, President of PCI. "We believe our services will be of great value to this region's life science community. Partnering with a validation firm that has high moral standards and values similar to ours is very attractive. We look forward to partnering with Sequence, Inc. and see this as a great opportunity for our firms to offer comprehensive, highly valued service solutions."

About Sequence, Inc.

Sequence, Inc. is proud to be celebrating its ten-year anniversary of providing validation and regulatory compliance services to the life sciences industry. Our areas of expertise include validation of laboratory instruments, information systems, and manufacturing equipment/processes as well as quality remediation, system configuration, and project management. We take pride in developing partner-like relationships with our clients and view employees as our most valuable asset.

About PCI, LLC.

PCI specializes in delivering instrument and equipment solutions that will reduce costs and enhance operational efficiencies while improving the compliance. Since 1996, our mission has been to provide personalized customer service, exceptional technical expertise, quality documentation and the integrity and ingenuity that our clients have grown to expect from the industry leader in calibration services.

For further information, visit www.sequencevalidation.com or email info@sequencevalidation.com for Sequence, Inc. and visit www.pci-llc.com or email PCI@pci-llc.com for PCI, LLC.

Contact:

Sequence, Inc.
Mike Putnam
919-844-7171

PCI, LLC
Andy Ferrell, President 
877-724-2257

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Sequence, Inc.; PCI, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
7. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
8. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
10. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
11. Netsmarts Focus on Innovation to Help Health and Human Service Providers Span the Spectrum of Care in the Healthcare 3.0 Environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):